Free Shipping & Returns in 24h on more than 300.000 products
Accumulate credit with every order
100% secure payment
More than 6 million products shipped
Hola,
Menú principal
Nombre categoria
Marcas Destacadas
Quamtrax Alpha Lipoic Acid - ALA 50 caps
Roll the mouse over to enlarge the image
imagen producto

Quamtrax Alpha Lipoic Acid - ALA 50 caps

Sold by
+ shipping See details
  • Product based on alpha lipoic acid , an ingredient that is considered a universal antioxidant since it prevents oxidative damage.

  • Dietary supplement.

  • Food supplements should not be used as a substitute for a balanced diet .

Sold by
+ shipping See details
This product is out of stock.
Preferably consume:
Do you have a Bulevip balance? See more
Share:

Do you have any questions?

Ask a question to the community if you have any questions about this product.

Product information Quamtrax Alpha Lipoic Acid - ALA 50 caps

Quamtrax Alpha Lipoic Acid (ALA) 50 caps is a food supplement in capsules to swallow based on alpha-lipoic acid. Food supplements should not be used as a substitute for a balanced and varied diet and a healthy lifestyle. Do not exceed the expressly recommended daily dose. Keep out of the reach of little kids.

Format:

Bottle of 50 caps.

How to use:

Take 2 capsules preferably before training.

Ingredients:

Alpha-lipoic acid (thiotic acid), Glazing agent: hydroxypropylmethylcellulose HPMC (empty capsule), Bulking agent: microcrystalline cellulose and anti-caking agent (magnesium stearate).

Nutritional information:

per capsule
Alpha Lipoic Acid 250mg


ADVERTENCIAS

Food supplements should not be used as a substitute for a balanced diet. The expressly recommended daily dose should not be exceeded. Keep this product out of the reach of small children.

Questions and answers from customers

No questions for this product yet.

Do you want to ask the community a question about this product?

Customer feedback

3.0
3.0 5-star
1 customer reviews
1 stars
2 stars
3 stars
4 stars
5 stars
With certificate of trust Opinions subject to scrutiny